Browse studies

Find your next paid study

4,469 recruiting studies matching your filters

Phase I Trial of IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

Background: Myeloid cells are a type of immune cell found in most tumors. Interleukin 12 (IL-12) is a protein that helps the immune system kill tumor cells. R…

Relapsed Solid Tumor MalignanciesRefractory Solid Tumor Malignancies

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07672483

Observational

Effect of a Femoral Venting Hole on Embolic Load in Prophylactic Intramedullary Nailing: A Feasibility Study

The purpose of this study is to measure intraoperative embolic burden during prophylactic intramedullary nailing of impending femur fractures in patients treat…

Femur Fracture

Estimated

~$10 – $6,250

The University of Texas Health Science Center, HoustonNCT07778238

Phase 1

Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a pe…

Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07332507

Phase 1

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)

This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tu…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05687136

Phase 1

A Phase 1 Trial of 8-Chloro-Adenosine in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myel…

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT05263284

Phase 4

A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization

Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of …

Heart FailureHeart Failure, DiastolicHeart Failure With Preserved Ejection Fraction+2 more

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT05585125

Phase 2

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Low Grade Upper Tract Urothelial Carcinoma

Estimated

~$10 – $8,750

Tyra Biosciences, IncNCT07265947

Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques

Background: Tics are involuntary movements and vocalizations. Some tics are organic: They are related to diagnosed disorders. Sometimes tics have other causes…

TicsFunctional Tics

Estimated

~$10 – $675

National Institute of Neurological Disorders and Stroke (NINDS)NCT07137442

Phase 2

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to sever…

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07415044

Phase 1

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recu…

Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT07779798

Phase 3

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed …

Metabolic Dysfunction Associated Steatohepatitis

Estimated

~$10 – $7,500

Boehringer IngelheimNCT06632457

LORRAINE 2.5/3.5 mm Distal Humerus System - Post-Market Surveillance Study

Distal humerus fractures are fractures of the lower part of the upper arm bone near the elbow. These fractures often require surgery using plates and screws to…

Intra-Articular or Extra-Articular Distal Humerus FractureDistal Humerus Fracture

Estimated

~$10 – $1,050

Bonebridge AGNCT07774091